Switch to:
Also traded in: Germany, Japan, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.76
TKPYY's Cash-to-Debt is ranked lower than
63% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. TKPYY: 0.76 )
Ranked among companies with meaningful Cash-to-Debt only.
TKPYY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.7  Med: 0.99 Max: N/A
Current: 0.76
Equity-to-Asset 0.48
TKPYY's Equity-to-Asset is ranked lower than
72% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TKPYY: 0.48 )
Ranked among companies with meaningful Equity-to-Asset only.
TKPYY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.48
0.47
0.76
Interest Coverage 9.84
TKPYY's Interest Coverage is ranked lower than
73% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. TKPYY: 9.84 )
Ranked among companies with meaningful Interest Coverage only.
TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 9.84
3.18
1856.28
Piotroski F-Score: 5
Altman Z-Score: 2.55
Beneish M-Score: -2.39
WACC vs ROIC
3.71%
7.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 10.45
TKPYY's Operating Margin % is ranked higher than
59% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. TKPYY: 10.45 )
Ranked among companies with meaningful Operating Margin % only.
TKPYY' s Operating Margin % Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 10.45
-7.27
35.13
Net Margin % 7.64
TKPYY's Net Margin % is ranked higher than
55% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. TKPYY: 7.64 )
Ranked among companies with meaningful Net Margin % only.
TKPYY' s Net Margin % Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 7.64
-8.2
25.85
ROE % 6.84
TKPYY's ROE % is ranked higher than
50% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. TKPYY: 6.84 )
Ranked among companies with meaningful ROE % only.
TKPYY' s ROE % Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 6.84
-6.33
15.12
ROA % 3.34
TKPYY's ROA % is ranked lower than
52% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. TKPYY: 3.34 )
Ranked among companies with meaningful ROA % only.
TKPYY' s ROA % Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.34
-3.29
12
ROC (Joel Greenblatt) % 29.08
TKPYY's ROC (Joel Greenblatt) % is ranked higher than
71% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. TKPYY: 29.08 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TKPYY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 29.08
-19.36
207.72
3-Year Revenue Growth Rate 5.20
TKPYY's 3-Year Revenue Growth Rate is ranked higher than
50% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. TKPYY: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TKPYY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
3-Year EBITDA Growth Rate -4.40
TKPYY's 3-Year EBITDA Growth Rate is ranked lower than
73% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. TKPYY: -4.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TKPYY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
3-Year EPS without NRI Growth Rate -18.50
TKPYY's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. TKPYY: -18.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TKPYY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
GuruFocus has detected 7 Warning Signs with Takeda Pharmaceutical Co Ltd $TKPYY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TKPYY's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:TEVA, NYSE:ZTS, NAS:MYL, OTCPK:SGIOF, OTCPK:ESALF, OTCPK:MKGAY, OTCPK:MTZXF, OTCPK:IPSEY, OTCPK:HLUKF, NYSE:PRGO, OTCPK:SFOSF, OTCPK:APNHF, NYSE:RDY, OTCPK:GZPHY, NYSE:VRX, OTCPK:HYPMY, NYSE:PTHN, OTCPK:HKMPY, OTCPK:RGEDF, NYSE:TARO » details
Traded in other countries:TKD.Germany, 4502.Japan, 0RN3.UK,
Headquarter Location:Japan
Takeda Pharmaceutical Co Ltd is a pharmaceutical company in Japan. It is primarily focused on four therapeutic areas; oncology, gastroenterology, cardiovascular/metabolic, and neurology. The company markets its products across Europe and emerging markets.

Takeda is Japan's largest pharmaceutical company, with annual revenue around $15 billion and a focus on four therapeutic areas: oncology, gastroenterology, vaccines, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include Azilva (blood pressure), leuprorelin (prostate cancer), and Trintellix (depression).

Ratios

vs
industry
vs
history
PE Ratio 34.15
TKPYY's PE Ratio is ranked lower than
62% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.96 vs. TKPYY: 34.15 )
Ranked among companies with meaningful PE Ratio only.
TKPYY' s PE Ratio Range Over the Past 10 Years
Min: 6.78  Med: 22.08 Max: 90.66
Current: 34.15
6.78
90.66
Forward PE Ratio 31.35
TKPYY's Forward PE Ratio is ranked lower than
79% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. TKPYY: 31.35 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 34.15
TKPYY's PE Ratio without NRI is ranked lower than
62% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.64 vs. TKPYY: 34.15 )
Ranked among companies with meaningful PE Ratio without NRI only.
TKPYY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.78  Med: 22.08 Max: 90.66
Current: 34.15
6.78
90.66
Price-to-Owner-Earnings 22.19
TKPYY's Price-to-Owner-Earnings is ranked higher than
67% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. TKPYY: 22.19 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TKPYY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.64  Med: 26.03 Max: 581.37
Current: 22.19
11.64
581.37
PB Ratio 2.28
TKPYY's PB Ratio is ranked higher than
60% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. TKPYY: 2.28 )
Ranked among companies with meaningful PB Ratio only.
TKPYY' s PB Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.56 Max: 2.44
Current: 2.28
1.22
2.44
PS Ratio 2.61
TKPYY's PS Ratio is ranked higher than
55% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. TKPYY: 2.61 )
Ranked among companies with meaningful PS Ratio only.
TKPYY' s PS Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.21 Max: 12.29
Current: 2.61
1.67
12.29
EV-to-EBIT 24.90
TKPYY's EV-to-EBIT is ranked lower than
60% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.48 vs. TKPYY: 24.90 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 11.95 Max: 46.2
Current: 24.9
-47.1
46.2
EV-to-EBITDA 13.26
TKPYY's EV-to-EBITDA is ranked higher than
64% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. TKPYY: 13.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -438  Med: 10.7 Max: 237.7
Current: 13.26
-438
237.7
Shiller PE Ratio 13.63
TKPYY's Shiller PE Ratio is ranked higher than
92% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.91 vs. TKPYY: 13.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
TKPYY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.78  Med: 11.14 Max: 13.69
Current: 13.63
8.78
13.69
Current Ratio 1.73
TKPYY's Current Ratio is ranked lower than
66% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TKPYY: 1.73 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.09 Max: 4
Current: 1.73
1.21
4
Quick Ratio 1.50
TKPYY's Quick Ratio is ranked lower than
59% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.73 Max: 3.64
Current: 1.5
1
3.64
Days Inventory 160.56
TKPYY's Days Inventory is ranked lower than
70% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. TKPYY: 160.56 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 160.56
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.52
TKPYY's Dividend Yield % is ranked higher than
85% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.58 vs. TKPYY: 1.52 )
Ranked among companies with meaningful Dividend Yield % only.
TKPYY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.52  Med: 4.22 Max: 6.48
Current: 1.52
1.52
6.48
Dividend Payout Ratio 1.05
TKPYY's Dividend Payout Ratio is ranked lower than
93% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. TKPYY: 1.05 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TKPYY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.33  Med: 0.62 Max: 1.77
Current: 1.05
0.33
1.77
Forward Dividend Yield % 3.03
TKPYY's Forward Dividend Yield % is ranked higher than
82% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.71 vs. TKPYY: 3.03 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.52
TKPYY's 5-Year Yield-on-Cost % is ranked higher than
100% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. TKPYY: 1.52 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TKPYY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.71  Med: 4.22 Max: 6.48
Current: 1.52
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.68
TKPYY's Price-to-Tangible-Book is ranked lower than
81% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. TKPYY: 8.68 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
TKPYY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.85  Med: 7.02 Max: 13.07
Current: 8.68
1.85
13.07
Price-to-Intrinsic-Value-Projected-FCF 2.27
TKPYY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. TKPYY: 2.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TKPYY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.14  Med: 1.44 Max: 2.27
Current: 2.27
1.14
2.27
Price-to-Median-PS-Value 1.18
TKPYY's Price-to-Median-PS-Value is ranked lower than
56% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. TKPYY: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TKPYY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1 Max: 5.16
Current: 1.18
0.81
5.16
Price-to-Graham-Number 3.63
TKPYY's Price-to-Graham-Number is ranked lower than
77% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. TKPYY: 3.63 )
Ranked among companies with meaningful Price-to-Graham-Number only.
TKPYY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.69  Med: 2.67 Max: 4.79
Current: 3.63
0.69
4.79
Earnings Yield (Greenblatt) % 4.02
TKPYY's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. TKPYY: 4.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TKPYY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.4  Med: 5.2 Max: 23.8
Current: 4.02
-3.4
23.8
Forward Rate of Return (Yacktman) % -27.33
TKPYY's Forward Rate of Return (Yacktman) % is ranked lower than
95% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. TKPYY: -27.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TKPYY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -46.9  Med: -16.7 Max: 15.8
Current: -27.33
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,890.59
EPS (TTM) $ 0.80
Beta0.42
Short Percentage of Float0.00%
52-Week Range $19.96 - 26.35
Shares Outstanding (Mil)1,567.34 (ADR)

Analyst Estimate

Mar17 Mar18 Mar19
Revenue (Mil $) 15,340 15,426 15,855
EPS ($) 0.65 0.81 0.46
EPS without NRI ($) 0.65 0.81 0.46
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.66%
Dividends per Share ($) 0.80 0.80 0.80
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Harrington Discovery Institute at University Hospitals Opens Call for Harrington Rare Disease Schola May 24 2017 
New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approache May 22 2017 
New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative C May 08 2017 
Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advanc Apr 27 2017 
Teva Is a Hold Nov 30 2016 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial Jun 26 2017
Why Lupron Could Continue to Generate Steady Revenue Jun 14 2017
Kyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017 May 25 2017
Harrington Discovery Institute at University Hospitals Opens Call for Harrington Rare Disease... May 24 2017
New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy... May 22 2017
Takeda Announces American Psychiatric Association (APA) Innovation Zone Activities May 19 2017
Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad... May 19 2017
Israel's BiomX raises $24 mln in private funding round May 15 2017
Takeda and GammaDelta Therapeutics Announce Collaboration to Advance Tissue-derived gamma delta... May 09 2017
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative... May 08 2017
New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative... May 08 2017
U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment Apr 28 2017
Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to... Apr 27 2017
Raleigh's PRA Health Sciences clocks double-digit growth in first quarter Apr 26 2017
Takeda Pharmaceutical Company Limited -- Moody's: Japan economic momentum building, on the back of... Apr 17 2017
Takeda's largest study brings dengue vaccine step closer Apr 05 2017
4 FDA Decisions to Watch Out for in Apr 2017 Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}